Skip to main content
Premium Trial:

Request an Annual Quote

Carl Zeiss, Cellomics Collaborate in NIH Small Molecule Screening Initiative

NEW YORK, July 19 (GenomeWeb News) - Carl Zeiss Microimaging and Cellomics announced on July 18 their involvement in two National Institutes of Health initiatives geared towards bringing small molecule screening to basic science researchers.


Zeiss and Cellomics will be contributing products and services to the NIH Molecular Libraries Screening Centers Network and overall Molecular Libraries Initiative. MLSCN research objectives include automation for target-based and cell-based phenotypic assays, software for managing molecular library screening, and informatics tools for data management.


Cellomics offers a variety of products for cell-based drug screening, including instrumentation and informatics software. Its confocal-based flagship cellular imaging platform, ArrayScan, utilizes Zeiss' Apotome optical sectioning technology.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.